Antisoma brings in HCC to beef up Euro financial PR

Biotech firm Antisoma - which develops drugs to treat cancer - is to step up its financial PR work across Europe in a bid to encourage people to buy its shares.

The London-based firm has drafted in HCC De Facto to handle continent-wide financial media relations, although Antisoma continues to retain Financial Dynamics in the UK.

HCC won a competitive pitch - held during February against two undisclosed agencies - for the contract, which will see it working in Germany, France, Switzerland and Scandinavia, supporting HCC’s investor relations work.

Antisoma head of corporate comms Daniel Elger said the firm already had a ‘significant’ continental shareholder base but that HCC had been hired as there ‘was room for growth’.

HCC’s London-based director David Dible heads a team on the account, which will be handled from the agency’s offices in London and Munich.

Following successful trials, Antisoma actively seeks pharmaceutical firm partners to help complete clinical development, file for regulatory approval and carry out marketing work.

Four Antisoma products are currently being evaluated in clinical trials and in November last year the firm signed a ‘marketing partnership’ with Roche to promote these products.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in